---
title: "UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285786109.md"
description: "UOB Kay Hian has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$257.00, while the stock closed at HK$188.90. The analyst consensus for BeOne Medicines is Strong Buy, with a target consensus of HK$252.79, indicating a potential upside of 33.82%. Additionally, DBS also maintains a Buy rating with a higher price target of HK$290.00."
datetime: "2026-05-09T00:30:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285786109.md)
  - [en](https://longbridge.com/en/news/285786109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285786109.md)
---

# UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

In a report released on May 7, from UOB Kay Hian maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$257.00. The company’s shares closed yesterday at HK$188.90.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

BeOne Medicines Ltd has an analyst consensus of Strong Buy, with a price target consensus of HK$252.79, a 33.82% upside from current levels. In a report released on May 7, DBS also maintained a Buy rating on the stock with a HK$290.00 price target.

### Related Stocks

- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [U10.SG](https://longbridge.com/en/quote/U10.SG.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [D05.SG](https://longbridge.com/en/quote/D05.SG.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [BeOne Medicines Ltd (6160) Gets a Buy from CMBC International](https://longbridge.com/en/news/285886964.md)